Opucolimab represents a highly specialized humanized monoclonal antibody specifically engineered to target the human Claudin 18.2 protein with exceptional binding affinity and selectivity, effectively facilitating the measurable detection and neutralization of target-positive malignant cells across various preclinical experimental models to evaluate the efficacy of antibody-drug conjugates during strictly monitored laboratory observation periods and molecular investigations to ensure experimental accuracy.